Abstract
Topiramate is approved for the preventive treatment of migraine in several countries based on the results of three large randomised, double-blind studies that showed that this compound was significantly more effective than placebo in migraine prophylaxis. We review the results of two studies: one which pooled data from the three controlled double-blind trials using 100 mg/day of topiramate, and an open-label extension of two of these trials in which patients received different topiramate doses for an eight-month maintenance period. The overall results confirm that topiramate is effective in reducing migraine frequency, and has a satisfactory tolerability profile.
Original language | English |
---|---|
Journal | Neurological Sciences |
Volume | 27 |
Issue number | SUPPL. 2 |
DOIs | |
Publication status | Published - Sep 2006 |
Keywords
- Clinical trial
- Migraine
- Open-label extension phase
- Pooled analysis
- Prophylaxis
- Topiramate
ASJC Scopus subject areas
- Neuroscience(all)
- Clinical Neurology